<DOC>
	<DOC>NCT01771250</DOC>
	<brief_summary>This study has two parts. Each participant will receive a daily injection of LY2605541 during one treatment period and a daily injection of insulin glargine during the other treatment period. Each treatment period is 3 to 4 weeks and is followed by procedures to look at how the body uses or stores fats while taking each study drug.</brief_summary>
	<brief_title>A Study of LY2605541 and Glargine on Fats in Participants With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetic for more than 1 year with glycated hemoglobin (HbA1c) of less than 8.5% Otherwise fit and healthy Non smoker Taking medication or supplements other than insulin to control diabetes. Suffered a hypoglycemic event in the last 12 months that required hospitalization or have poor awareness of hypoglycemia Taking fibrates, thyroid replacement therapy, testosterone, beta blockers or systemic corticosteroids</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>